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Background: Androgen deprivation therapy (ADT) plays a central role in the management of men with prostate cancer. In population-based 
analysis, low serum testosterone is associated with cardiovascular disease. It remains unclear whether patients with prostate cancer received ADT 
have a high risk of cardiovascular morbidities.
Method and Result: This single-centered observational study included 739 consecutive Chinese men with prostate cancer during 1994 to 2011. 
Patients with pre-existing coronary artery disease, heart failure, atrial fibrillation, ischemic and/or hemorrhagic stroke, and diabetes were excluded. 
Consequentially, 313 patients (55%) on ADT, and 253 patients (45%) not on ADT were included in the final analysis. After a mean follow-up of 
9.2 years, patients on ADT had a higher incidence of new-onset diabetes mellitus (6.7% vs. 1.6%, p=0.003), a higher incidence of coronary artery 
disease (4.2% vs. 0.0%, p=0.001), a higher incidence of new-onset atrial fibrillation (4.2% vs. 0.8%, p=0.01), and a higher incidence of new-onset 
heart failure (4.8% vs. 0.0%, p<0.001). In addition, patients on ADT had a higher incidence ischemic stroke (4.5% vs. 0.4%, p<0.01). In multivariate 
logistic regression, the use of ADT remained predictive of all these adverse cardiovascular events.
Conclusions: We observed in a cohort of Chinese prostate cancer men that ADT use was associated with increased risk cardiovascular events. 
Frequent monitoring may allow more aggressive preventive management.
